Fidson joins 11 Roche-backed generic flu drug makers for 129 countries

Fidson Healthcare Plc has been selected by the Medicines Patent Pool (MPP) as one of 11 manufacturers licensed to develop generic versions of Roche’s influenza antiviral baloxavir marboxil for 129 countries, a supply signal UAE clinics, insurers and pharmacies should track before the 2026-27 winter season.

The highest-stakes readers are pharmacy procurement leads, CFOs and medical directors. For Dubai operators, the immediate question is whether a lower-cost single-dose flu antiviral could enter formulary discussions once it has a Ministry of Health and Prevention (MOHAP) registration and an approved UAE price. Dubai Health Authority (DHA) facilities, Department of Health Abu Dhabi (DOH) facilities and northern emirates providers regulated by MOHAP cannot treat the MPP announcement as a local supply approval.

What Roche and MPP licensed

BusinessDay Nigeria reported on 3 October 2026 that Fidson was selected under a voluntary licence for generic baloxavir marboxil, Roche’s single-dose oral influenza treatment sold as Xofluza. The MPP said the licence allows selected manufacturers to develop, manufacture and supply affordable generic baloxavir in 129 low- and middle-income countries, subject to local regulatory authorisation.

The selected manufacturers include companies in Brazil, China, India, Indonesia, Malaysia, Nigeria, Uganda, Ukraine and Vietnam. MPP said the licence followed its May 2026 agreement with Roche. The agreement gives sublicensees access to a technical data package, reference products for bioequivalence studies and regulatory waivers where needed.

“This is about preparing before the next health emergency, rather than after it starts.” Charles Gore, executive director, Medicines Patent Pool, said in MPP’s announcement of the implementation phase.

Roche says Xofluza is approved in more than 80 countries for uncomplicated influenza types A and B. The licence does not automatically place generic baloxavir on UAE pharmacy shelves. It creates a wider manufacturing base that UAE buyers can monitor when suppliers seek Gulf registrations.

Why UAE operators should care

For Dubai clinics and pharmacies, the operational issue is substitution planning. Baloxavir is a one-dose treatment, while oseltamivir is usually dispensed as a multi-day course. If a registered generic reaches the UAE at a lower approved price, pharmacy teams may need new protocols for eligibility, counselling and payer authorisation during peak influenza weeks.

For CFOs and insurers, the price question remains open. A public UAE online pharmacy listing for Tamiflu 75 mg showed AED 144.50 when checked in October 2026, but that is an oseltamivir reference point, not a baloxavir benchmark. Operators should confirm current prices through the MOHAP registered medical product directory, which lists registered medicines, active ingredients, package sizes and selling prices.

• DHA providers in Dubai should check whether any baloxavir product has MOHAP registration before adding it to seasonal flu pathways.
• DOH Abu Dhabi providers should compare antiviral prescribing guidance with payer rules under Daman and Thiqa where applicable.
• Northern emirates pharmacies should use MOHAP channels for product registration status and approved selling prices.
• Insurers including Sukoon should watch whether one-dose therapy changes outpatient drug spend, prior authorisation rules or emergency department diversion plans.

MOHAP’s single medical product pricing certificate service has an average service time of 90 working days and a fee of AED 500 per medical product pricing certificate, according to MOHAP service material published in 2026. That timeframe matters for distributors planning winter tenders.

What to watch next

The first UAE signal will be a registration or pricing entry, not the MPP licence itself. Procurement teams should ask suppliers for the marketing authorisation holder, country of origin, MOHAP registration number, approved pack size and approved UAE selling price before comparing baloxavir with existing oseltamivir stock.

Medical directors should also avoid assuming interchangeability. DOH’s 2025 seasonal influenza guidance referred to oseltamivir, zanamivir and peramivir in treatment recommendations. Any addition of baloxavir in UAE clinical pathways would need local formulary review and prescriber education.

The commercial opportunity is narrow but real. If generic baloxavir gains UAE registration, clinics could market faster flu treatment visits during winter, pharmacies could review antiviral inventory depth, and insurers could test whether earlier outpatient treatment reduces complications in high-risk members. Until then, the action item is verification. UAE readers can start with the UAE Open Healthcare Directory to identify licensed pharmacy providers in Dubai and compare access points before the influenza season tightens supply.